UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39103 CABALETTA BIO, INC. (Exact name of Registrant as specified in its Charter) Delaware 82-1685768 (State or other jurisdiction of ...

产品和技术研发 - Cabaletta Bio公司致力于开发和推出针对自身免疫性疾病患者的首个治愈性靶向细胞疗法[5] - CABA™平台拥有治愈或治疗数十种自身免疫性疾病的生物学机会[10] - CABA-201是针对自身免疫性疾病的CAR T细胞疗法[13] - DSG3-CAART和MuSK-CAART是针对自身免疫性疾病的嵌合抗体受体T细胞[19] - DesCAARTes™研究正在进行中，旨在评估DSG3-CAART在口腔黏膜天疱疮患者中的最大耐受剂量和安全性[23] - MuSK-CAART的首次人体试验策略受DesCAARTes™研究启发，正在进行开放标签研究以确定MuSK-CAART的最大耐受剂量和评估安全性[27] 未来展望 - 预计未来12-18个月内将有多个潜在临床催化剂，包括CABA-201、DSG3-CAART、MuSK-CAART等，现金储备可支持至2025年第一季度[33] - 预计2023年上半年CABA-201将获得IND清关，2024年上半年将有CABA-201和DSG3-CAART的初步临床数据发布[33] 市场扩张和并购 - Cabaletta公司的CABA-201在自身免疫性疾病患者中具有潜力，预计在2023年上半年获得IND批准[6] - CABA-201在自身免疫性疾病领域的发展加速，具有独特的转化洞见和及时的CAART临床实施记录[17] 其他有价值的信息 - 公司在自身免疫性疾病领域具有操作成功的记录，涵盖了临床前、临床、制造和监管领域[32] - 三阶段制造策略允许有效配置资本，利用经验丰富的合作伙伴，包括Penn合作伙伴提供的细胞处理能力，CDMOs进行载体和细胞处理，以及Cabaletta拥有的制造设施的建设和扩大规模[30] - Cabaletta Bio的领导团队包括总裁兼CEO Steven Nichtberger，首席科学官Samik Basu等，董事会成员包括Catherine Bollard等[31]

Cabaletta Bio° Corporate Presentation SEPTEMBER 2022 © 2022 Cabaletta Bio. All rights reserved. Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," ...

Cabaletta Bio° Corporate Presentation AUGUST 2022 © 2022 Cabaletta Bio. All rights reserved. Disclaimer 2 The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," " ...

Cabaletta Bio° Corporate Presentation MAY 2022 © 2022 Cabaletta Bio. All rights reserved. Disclaimer 2 The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," "Cab ...

Cabaletta Bio° Corporate Presentation MARCH 2022 © 2022 Cabaletta Bio. All rights reserved. Disclaimer 2 The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," "C ...

Cabaletta Bio° Corporate Presentation MARCH 2022 © 2022 Cabaletta Bio. All rights reserved. Disclaimer 2 The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," "C ...

Cabaletta Bio° Corporate Presentation SEPTEMBER 2021 © 2021 Cabaletta Bio. All rights reserved. Disclaimer 2 The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our, ...

Cabaletta Bio° Corporate Presentation APRIL 2021 © 2021 Cabaletta Bio. All rights reserved. Disclaimer 2 The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," "C ...

Cabaletta Bio" Corporate Presentation OCTOBER 2020 © 2020 Cabaletta Bio. All rights reserved. Disclaimer 2 The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (collectively, the "Presentation") has been prepared by Cabaletta Bio, Inc. ("we," "us," "our," ...